AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation

Introduction AATF/Che-1 over-expression in different tumors is well known and its effect on tumorigenicity is mainly due to its central role demonstrated in the oncogenic pathways of solid tumors, where it controls proliferation and viability. The effect exerted by tumors overexpressing Che-1 on the immune response has not yet been investigated. Methods Starting from ChIP-sequencing data we confirmed Che-1 enrichment on Nectin-1 promoter. Several co-cultures experiments between NK-cells and tumor cells transduced by lentiviral vectors carrying Che-1-interfering sequence, analyzed by flow-cytometry have allowed a detailed characterization of NK receptors and tumor ligands expression. Results Here, we show that Che-1 is able to modulate the expression of Nectin-1 ligand at the transcriptional level, leading to the impairment of killing activity of NK-cells. Nectin-1 down-modulation induces a modification in NK-cell ligands expression able to interact with activating receptors and to stimulate NK-cell function. In addition, NK-cells from Che-1 transgenic mice, confirming a reduced expression of activating receptors, exhibit impaired activation and a preferential immature status. Discussion The critical equilibrium between NK-cell ligand expression on tumor cells and the interaction with NK cell receptors is affected by Che-1 over-expression and partially restored by Che-1 interference. The evidence of a new role for Che-1 as regulator of anti-tumor immunity supports the necessity to develop approaches able to target this molecule which shows a dual tumorigenic function as cancer promoter and immune response modulator.

[1]  A. Hidalgo-Miranda,et al.  NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia , 2022, Frontiers in Oncology.

[2]  K. Haynes,et al.  B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12 , 2022, Scientific Reports.

[3]  S. Nathan,et al.  Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia , 2022, Journal of immunology research.

[4]  Yue Zhang,et al.  CRISPR/Cas9 ribonucleoprotein (RNP) complex enables higher viability of transfected cells in genome editing of acute myeloid cells , 2022, Annals of translational medicine.

[5]  W. Fang,et al.  NKG2D discriminates diverse ligands through selectively mechano‐regulated ligand conformational changes , 2021, The EMBO journal.

[6]  D. Samanta,et al.  Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[7]  L. Ruggeri,et al.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications , 2021, International journal of molecular sciences.

[8]  Martyna Poprzeczko,et al.  Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia , 2021, Cancers.

[9]  N. Tumino,et al.  Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer , 2020, Frontiers in Immunology.

[10]  N. Tumino,et al.  NK cells and ILCs in tumor immunotherapy. , 2020, Molecular aspects of medicine.

[11]  T. Díaz,et al.  Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma , 2020, Clinical Cancer Research.

[12]  Behnaz Valipour,et al.  NK cells: An attractive candidate for cancer therapy , 2019, Journal of cellular physiology.

[13]  M. Carlsten,et al.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells , 2019, Front. Immunol..

[14]  Young-Uk Cho,et al.  Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia , 2019, AntiCancer Research.

[15]  P. Palma,et al.  DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection? , 2019, International journal of molecular sciences.

[16]  A. Pera,et al.  DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy , 2019, Cancers.

[17]  E. Munari,et al.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications , 2019, Cellular & Molecular Immunology.

[18]  E. Munari,et al.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications , 2019, Cellular & Molecular Immunology.

[19]  J. Markert,et al.  Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression , 2018, Scientific Reports.

[20]  Ming Li,et al.  Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion , 2018, Oncology letters.

[21]  G. Lal,et al.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy , 2017, Front. Immunol..

[22]  G. Blandino,et al.  Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization , 2017, Journal of experimental & clinical cancer research : CR.

[23]  Jianji Pan,et al.  Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma , 2017, Oncotarget.

[24]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[25]  A. Santoni,et al.  Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies , 2015, Front. Immunol..

[26]  G. Tonon,et al.  Che‐1‐induced inhibition of mTOR pathway enables stress‐induced autophagy , 2015, The EMBO journal.

[27]  S. Granjeaud,et al.  Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer , 2015, Oncotarget.

[28]  Sunghoon Kim,et al.  MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer , 2014, BMC Cancer.

[29]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[30]  F. Locatelli,et al.  Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications , 2014, International Archives of Allergy and Immunology.

[31]  M. Smyth,et al.  DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins , 2014, Immunology and cell biology.

[32]  G. Salles,et al.  Monitoring NK cell activity in patients with hematological malignancies , 2013, Oncoimmunology.

[33]  Shuji Sato,et al.  Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers , 2013, Molecular Cancer.

[34]  S. Almo,et al.  Structure of Nectin-2 reveals determinants of homophilic and heterophilic interactions that control cell–cell adhesion , 2012, Proceedings of the National Academy of Sciences.

[35]  M. Smyth,et al.  Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. , 2012, Current opinion in immunology.

[36]  M. Capogrossi,et al.  Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals , 2012, Molecular biology of the cell.

[37]  Anshu Malhotra,et al.  NK cells: immune cross-talk and therapeutic implications. , 2011, Immunotherapy.

[38]  M. Disis Immune regulation of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Barbara Benassi,et al.  Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. , 2010, Cancer cell.

[40]  C. Roth,et al.  Maturation of mouse NK cells is a 4-stage developmental program. , 2009, Blood.

[41]  M. Martinetti,et al.  Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. , 2009, Blood.

[42]  C. Passananti,et al.  Che-1/AATF, a multivalent adaptor connecting transcriptional regulation, checkpoint control, and apoptosis. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[43]  C. Leonetti,et al.  Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. , 2006, Cancer cell.

[44]  Stephen Y. Oh,et al.  Nectin-1 expression in the normal and neoplastic human uterine cervix. , 2006, Archives of pathology & laboratory medicine.

[45]  E. Lanino,et al.  Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.

[46]  L. Moretta,et al.  PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.

[47]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[48]  M. Wiznerowicz,et al.  Conditional Suppression of Cellular Genes: Lentivirus Vector-Mediated Drug-Inducible RNA Interference , 2003, Journal of Virology.

[49]  C. Passananti,et al.  Identification of a novel partner of RNA polymerase II subunit 11, Che‐1, which interacts with and affects the growth suppression function of Rb , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[51]  A. Utani,et al.  The expression of nectin-1alpha in normal human skin and various skin tumours. , 2003, The British journal of dermatology.

[52]  J. Luhm,et al.  NK cells: a lesson from mismatched hematopoietic transplantation. , 2003, Trends in immunology.